STRATA Skin Sciences posts investor presentation
STRATA Skin Sciences, Inc. furnished an investor presentation to the market by posting it on its website and attaching it as Exhibit 99.1 to a current report.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
STRATA Skin Sciences, Inc. furnished an investor presentation to the market by posting it on its website and attaching it as Exhibit 99.1 to a current report. The presentation is dated August 2025 and is intended to provide additional information to investors about the company.
The material in this investor presentation, and the related exhibit, is being furnished under a current report rather than filed, which means it is not subject to certain liability provisions of the securities laws and is not automatically incorporated into other securities filings unless specifically referenced.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did STRATA Skin Sciences (SSKN) disclose in this 8-K?
The company furnished an investor presentation by posting it on its website and attaching it as Exhibit 99.1 to the report.
Where can investors find the STRATA Skin Sciences (SSKN) investor presentation?
The investor presentation was posted on the company’s website at https://strataskinsciencesinc.gcs-web.com/ and attached as Exhibit 99.1.
Is the STRATA Skin Sciences (SSKN) investor presentation considered filed with the SEC?
No. The company states the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liability or automatically incorporated into other filings.
What exhibits were included with this STRATA Skin Sciences (SSKN) report?
The report includes Exhibit 99.1 (Investor Presentation dated August 2025) and Exhibit 104 (Cover Page Interactive Data File).
Who signed the STRATA Skin Sciences (SSKN) current report?
The report was signed on behalf of the company by John Gillings, Chief Accounting Officer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 18, 2025
(Exact Name of Registrant Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: 215 -619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
| Item 7.01. |
Regulation FD Disclosure.
|
On August 18, 2025, STRATA Skin Sciences, Inc. (the “Company”) posted
an investor presentation to its website at https://strataskinsciencesinc.gcs-web.com/. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth in this item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as
shall be expressly set forth by specific reference in any such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
The following presentation is furnished as an exhibit to this Current Report on Form 8-K and shall not be deemed to be “filed”:
|
Exhibit No.
|
Exhibit Description
|
|
99.1
|
Investor Presentation dated August 2025, issued by Strata Skin Sciences, Inc.
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
STRATA SKIN SCIENCES, INC.
|
|||
|
Date: August 18, 2025
|
By:
|
/s/ John Gillings
|
|
|
John Gillings
|
|||
|
Chief Accounting Officer
|
|||